Diabetes Care:HbA1c低水平或可预测普通人群死亡风险

2012-08-10 医学论坛网 医学论坛网

8月1日,《糖尿病护理》(Diabetes Care)杂志发表了美国学者的一项研究成果,在非糖尿病患者的普通人群中,糖化血红蛋白(HbA1c)水平低可能是死亡风险的泛化标志物。 此项前瞻性队列研究共纳入13288例受试者。利用Logistic回归分析确认低HbA1c(<5%)的横断面相关性,并利用Cox比例风险模型评估低HbA1c与死因别死亡率的相关性。 结果显示,与HbA1c处于正常范

8月1日,《糖尿病护理》(Diabetes Care)杂志发表了美国学者的一项研究成果,在非糖尿病患者的普通人群中,糖化血红蛋白(HbA1c)水平低可能是死亡风险的泛化标志物。

此项前瞻性队列研究共纳入13288例受试者。利用Logistic回归分析确认低HbA1c(<5%)的横断面相关性,并利用Cox比例风险模型评估低HbA1c与死因别死亡率的相关性。

结果显示,与HbA1c处于正常范围的受试者相比,低HbA1c者较为年轻,吸烟可能性较低,体质指数(BMI)、白细胞计数和纤维蛋白原水平较低,并且高胆固醇血症患病率以及冠心病既往患病率较低。然而,低HbA1c者贫血可能性较高,并且平均红细胞压积较高。在以HbA1c为5.0~5.7为参照组的校正Cox模型中,HbA1c<5.0%与全因死亡(危险比[HR] 1.32)和癌症死亡(HR 1.47)风险显著升高具有相关性;心血管性和呼吸系统性死亡风险具有非显著升高趋势。HbA1c与肝脏疾病住院之间呈J形相关。

doi:10.2337/dc11-2531
PMC:
PMID:

Low Hemoglobin A1c in Nondiabetic Adults

An elevated risk state?

Vikas Aggarwal, MD1, Andrea L.C. Schneider, PHD2,3 and Elizabeth Selvin, PHD, MPH

OBJECTIVE To identify predictors of low hemoglobin A1c (HbA1c) (<5.0%) and to investigate the association of low HbA1c with cause-specific mortality and risk of liver disease hospitalization.

RESEARCH DESIGN AND METHODS Prospective cohort study of 13,288 participants in the Atherosclerosis Risk in Communities Study. Logistic regression was used to identify cross-sectional correlates of low HbA1c and Cox proportional hazards models were used to estimate the association of low HbA1c with cause-specific mortality.

RESULTS Compared with participants with HbA1c in the normal range (5.0 to <5.7%), participants with low HbA1c were younger, less likely to smoke, had lower BMI, lower white cell count and fibrinogen levels, and lower prevalence of hypercholesterolemia and history of coronary heart disease. However, this group was more likely to have anemia and had a higher mean corpuscular volume. In adjusted Cox models with HbA1c of 5.0 to <5.7% as the reference group, HbA1c <5.0% was associated with a significantly increased risk of all-cause mortality (hazard ratio [HR]: 1.32, 95% CI: 1.13–1.55) and of cancer death (1.47, 95% CI: 1.16–1.84). We also noted nonsignificant trends toward increased risk of death from cardiovascular causes (1.27; 95% CI, 0.93–1.75) and respiratory causes (1.42, 95% CI: 0.78–2.56). There was a J-shaped association between HbA1c and risk of liver disease hospitalization.

CONCLUSIONS No single cause of death appeared to drive the association between low HbA1c and total mortality. These results add to evidence that low HbA1c values may be a generalized marker of mortality risk in the general population.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1900987, encodeId=ad17190098ed4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 31 09:31:00 CST 2013, time=2013-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759178, encodeId=9bc01e59178d5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 16 00:31:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015879, encodeId=1f1d20158e9bd, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Feb 15 15:31:00 CST 2013, time=2013-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636547, encodeId=e706163654e2f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Nov 05 14:31:00 CST 2012, time=2012-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255413, encodeId=e74f125541364, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 12 02:31:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614749, encodeId=7ec11614e4967, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Sun Aug 12 02:31:00 CST 2012, time=2012-08-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1900987, encodeId=ad17190098ed4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 31 09:31:00 CST 2013, time=2013-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759178, encodeId=9bc01e59178d5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 16 00:31:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015879, encodeId=1f1d20158e9bd, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Feb 15 15:31:00 CST 2013, time=2013-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636547, encodeId=e706163654e2f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Nov 05 14:31:00 CST 2012, time=2012-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255413, encodeId=e74f125541364, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 12 02:31:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614749, encodeId=7ec11614e4967, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Sun Aug 12 02:31:00 CST 2012, time=2012-08-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1900987, encodeId=ad17190098ed4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 31 09:31:00 CST 2013, time=2013-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759178, encodeId=9bc01e59178d5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 16 00:31:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015879, encodeId=1f1d20158e9bd, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Feb 15 15:31:00 CST 2013, time=2013-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636547, encodeId=e706163654e2f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Nov 05 14:31:00 CST 2012, time=2012-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255413, encodeId=e74f125541364, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 12 02:31:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614749, encodeId=7ec11614e4967, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Sun Aug 12 02:31:00 CST 2012, time=2012-08-12, status=1, ipAttribution=)]
    2013-02-15 Smile2680
  4. [GetPortalCommentsPageByObjectIdResponse(id=1900987, encodeId=ad17190098ed4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 31 09:31:00 CST 2013, time=2013-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759178, encodeId=9bc01e59178d5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 16 00:31:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015879, encodeId=1f1d20158e9bd, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Feb 15 15:31:00 CST 2013, time=2013-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636547, encodeId=e706163654e2f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Nov 05 14:31:00 CST 2012, time=2012-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255413, encodeId=e74f125541364, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 12 02:31:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614749, encodeId=7ec11614e4967, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Sun Aug 12 02:31:00 CST 2012, time=2012-08-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1900987, encodeId=ad17190098ed4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 31 09:31:00 CST 2013, time=2013-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759178, encodeId=9bc01e59178d5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 16 00:31:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015879, encodeId=1f1d20158e9bd, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Feb 15 15:31:00 CST 2013, time=2013-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636547, encodeId=e706163654e2f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Nov 05 14:31:00 CST 2012, time=2012-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255413, encodeId=e74f125541364, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 12 02:31:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614749, encodeId=7ec11614e4967, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Sun Aug 12 02:31:00 CST 2012, time=2012-08-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1900987, encodeId=ad17190098ed4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 31 09:31:00 CST 2013, time=2013-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759178, encodeId=9bc01e59178d5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 16 00:31:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015879, encodeId=1f1d20158e9bd, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Feb 15 15:31:00 CST 2013, time=2013-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636547, encodeId=e706163654e2f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Nov 05 14:31:00 CST 2012, time=2012-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255413, encodeId=e74f125541364, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 12 02:31:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614749, encodeId=7ec11614e4967, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Sun Aug 12 02:31:00 CST 2012, time=2012-08-12, status=1, ipAttribution=)]

相关资讯

HbA1c检测影响血糖监控

  上世纪九十年代的中晚期,糖尿病控制及并发症试验(DCCT)和英国大规模的2型糖尿病控制与并发症关系研究(UKPDS)的研究结果显示,强化的血糖控制能显著降低长期糖尿病并发症的危险和进展。这些结果强调了HbA1c在糖尿病患者中血糖控制监测的作用,并为其作为特异的糖尿病治疗目标的运用搭建了舞台。从那时起,大多数临床糖尿病组织都将HbA1c纳入糖尿病的治疗目标。因为HbA1c极小的差异就能造成并发症

HbA1c检测精度影响血糖监控

 上世纪九十年代的中晚期,糖尿病控制及并发症试验(DCCT)和英国大规模的2型糖尿病控制与并发症关系研究(UKPDS)的研究结果显示,强化的血糖控制能显著降低长期糖尿病并发症的危险和进展。这些结果强调了HbA1c在糖尿病患者中血糖控制监测的作用,并为其作为特异的糖尿病治疗目标的运用搭建了舞台。从那时起,大多数临床糖尿病组织都将HbA1c纳入糖尿病的治疗目标。因为HbA1c极小的差异就能造成并发症患

AIM:糖尿病伴肾病者必须控制好HbA1c水平

美国阿拉贝塔大学的一组研究人员通过观察性研究发现,患有糖尿病和3或4期慢性肾脏疾病的患者,糖化血红蛋白(HbA1c)水平过高和过低均与预后差有关。其研究结果近日被发表在《内科学文献》(Archives of Internal Medicine)杂志上。 阿拉贝塔大学的Marcello Tonelli博士指出,糖化血红蛋白水平过高与一系列临床事件有关,包括高死亡风险、肾脏疾病恶化、新的终末期肾脏疾

可根据入院时HbA1c确定出院后降糖药剂量

费城——根据一项纳入224例2型糖尿病住院患者的前瞻性随机初步研究的结果,入院时糖化血红蛋白A1c(HbA1c)水平可指导出院后的糖尿病治疗。 埃默里大学Grady纪念医院糖尿病与内分泌科主任Guillermo E. Umpierrez博士介绍,受试者的HbA1c平均水平从入院时的8.4%降至4周时的7.9%, 12周时(出院后至少2周)进一步降至7.3%。“既然我们这所市级医院能够达到这一治疗

HbA1c不可靠时可改测糖化白蛋白(果糖胺)

      美国杜克大学的Thomas L. O' Connell博士在美国医师协会(ACP)年会上指出,如果遇到糖化血红蛋白A1c(HbA1c)与血糖监测数据不一致的情况,应当提高警惕。   Connell博士强调,由于任何可影响血红蛋白的因素都会干扰HbA1c检查,因此HbA1c与血糖监测结果不一致的情况实际上相当常见。例如,正在接受血液透析、近期接受了输血、患

HbA1c与死亡率之间是否存在U型曲线

   两年前一项报告中,柯里(Currie)等人通过英国全科医学数据库获取了27965例口服多种降糖药及20005例初始口服降糖药随后胰岛素治疗的糖尿病患者信息,随访5年发现,死亡率最低的是平均糖化血红蛋白(HbA1c)7.5%的患者,HbA1c平均值高于或低于这个数值都与存活率低相关。特别是胰岛素治疗的患者,HbA1c10.5%或6.0%患者死亡率几乎是HbA1c7.5%患者的2倍。